Born: 1982.
Education: MSc. Pharmaceutical Sciences, BSc. Biotechnology.
Other current appointments: Senior project manager, KLIFO A/S, Denmark
Work experience: Having worked with both major global pharmaceutical companies and small biotech start-ups, Thomas has more than 15 years of experience working with the clinical trials,. Thomas’ work has been focused on all aspects of clinical trial managing including budget and timelines management, sponsor oversight, protocol and informed consent development, development study-specific documents, team training, data cleaning, and patient recruitment.
Holdings: None.
Member of:
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read moreThe US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read moreOlof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more